Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema

Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol 2019; 181: 604–6. Burlando M, Cozzani E, Russo R, Parodi A. Atopic-like dermatitis after secukinumab injection: A case report. Dermatol Ther 2019; 32: e12751. Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in the course of anti-IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther 2020; 20: 665–72. Puşcaş AD, Cătană A, Puşcaş C, et al. Psoriasis: association of interleukin-17 gene polymorphisms with severity and response to treatment. Exp Ther Med 2019; 18: 875–80. Suto H, Nambu A, Morita H, et al. IL-25 enhances TH17 cell-mediated contact dermatitis by promoting IL-1β production by dermal dendritic cells. J Allergy Clin Immunol 2018; 142: 1500–9. Blauvelt A, Chiricozzi A. The Immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 2018; 55: 379–90.